Lone Pine Capital’s Q1 2025 13F portfolio value dropped to $11.58B, with holdings reduced from 30 to 22, focusing on top tech ...

While Novo Nordisk stock has underperformed since my Strong Buy rating four months ago, the long-term investment thesis ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Phase 2a data on Skye Bioscience's (NASDAQ:SKYE) cannabinoid-1 receptor blocker (CB1) for obesity, nimacimab, should be released in late Q3 or early Q4, the company's CEO confirmed to Seeking Alpha.

The stock market rose within a mini-range for the week amid Israel-Iran headlines and the Federal Reserve's rate outlook.

See the latest Eli Lilly and Co stock price (LLY:XNYS), related news, valuation, dividends and more to help you make your investing decisions.

Baron Funds, an investment management company, released its “Baron Fifth Avenue Growth Fund” first quarter 2025 investor ...

LLY Factor-Based Stock Analysis June 11, 2025 — 08:06 am EDT Written by John Reese for Validea -> ...

On June 5, TD Cowen analysts trimmed the price target for Eli Lilly and Company (NYSE:LLY) from $1,050 to $960, while reiterating a Buy rating on the stock. This target price adjustment aligns ...

Below is Validea's guru fundamental report for ELI LILLY AND CO (LLY). Of the 22 guru strategies we follow, LLY rates highest using our P/B Growth Investor model based on the published strategy of ...